SELIM, A. M. R., N. Al-Hadithy, M. Hegazy, A. S. Barakat, and H. Abdelazeem,
A novel parameter for lag screw placement in patients with proximal femur fractures,
, Cairo, Cairo University, 2022.
Makar, H. A. S., R. M. Gaafar, A. A. Bahnassy, and A. M. Helal,
Prognostic Effect of Drug Resistance of Glutathione-STransferase in Non Small Lung Cancer,
, Egypt, Cairo University, 2012.
AbstractBackground And Objective: It has been known that the expression levels
GST were correlated with tumorigenesis and prognosis. The aim of this study is to
investigate the relationship between expression levels of GST in tissue &serum
level, and clinicopathologic parameters, survival &response to platinum
containing regimen used in treatment of patients with lung cancer. Methods: The
expression levels of GST were detected by immunohistochemical staining on
tissue micro-array sections made of 64 cases of lung cancer and serum samples
were collected from 68 cases pre-treatment, post 2nd Cycle & post 4th as such.10
control cases serum samples were also examined. The results were compared with
relevant clinical and pathologic data. Results: There were 50 males (73.6%) and
18 females (26.4%), their ages ranged from 30 to 69 years with a median of 55
years. The pathology included 24 patients had squamous cell carcinoma and 44
non squamous cell carcinomas. PS was I in 36 (52.9%) cases while PS was II in
the remaining 32 cases (47.1%). Sixty cases were presented with either stage IIIB
or IV. Serum samples pre-treatment could express tissue expression of GST
(P<0.001). We also found that GST in serum rose markedly in progressive disease
compared to minor rise in stable disease in post 2nd & 4th cycle samples compared
to pre-treatment level, while it decreased in disease responding cases (PR) p<0.001
and 0.015 consecutively. A strong correlation between early& late stages disease
and both OS (p=0.03) & PFS (p= 0.003) was found. There were no significant
correlations between tissue expression of GST and either overall survival (P =
0.66) nor progression free survival. (P =0.34), same as serum GST pre-treatment
level (p= 0.68 & 0.106). Multivariate analysis using Cox regression model showed
that expression levels of GST & serum level pretreatment were not the important
independent prognostic factors for survival. Conclusion: Serum GST pretreatment
level in non small cell lung cancer could predict tissue expression of GST.
Changes in this level, whether rising or declining, could predict response to
platinum containing regimen.